首页|期刊导航|Pharmacoeconomics and Policy|Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic Evaluations

Comments on the 2025 Edition of China Guidelines for Pharmacoeconomic EvaluationsOA

中文摘要

Pharmacoeconomic evaluations have emerged as a cornerstone of evidence-based healthcare decision-making in China,particularly since 2017 when it was formally integrated into price negotiations for innovative drugs seeking inclusion in the National Reimbursement Drug List(NRDL).The standardization of pharmacoeconomic evaluations is essential to enhancing both the research accuracy and practical applicability in policy contexts.Since 2011,the Pharmacoeconomics Committee of the Chinese Pharmaceutical Association(CPA)has convened multidisciplinary expert teams to develop the China Guidelines for Pharmacoeconomic Evaluations.

Jing Wu;Gordon G.Liu

School of Pharmaceutical Science and Technology,Faculty of Medicine,Tianjin University,Tianjin 300072,China Institute of Health Economics and Policy,Tianjin University,Tianjin 300072,China Center for Social Science Survey and Data,Tianjin University,Tianjin 300072,ChinaInstitute for Global Health and Development,Peking University,Beijing 100871,China National School of Development,Peking University,Beijing 100871,China

医药卫生

evidence based healthcarenational reimbursement drug list nrdlinnovative drugsprice negotiationspharmacoeconomic evaluationsChina guidelinesstandardization

《Pharmacoeconomics and Policy》 2026 (1)

P.1-3,3

supported by the Major Project of the National Social Science Fund of China(Grant No.:25&ZD143).

10.1016/j.pharp.2026.03.003

评论